Alumis Inc. (ALMS) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Alumis Inc. (ALMS) posted $24.05M in revenue for fiscal 2025, with a net loss of $243.32M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Alumis Inc.
Alumis Inc. has grown revenue from $0 to $24.05M over the last 4 fiscal years.
Net margin sits at -1011.7%.
The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Alumis Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Alumis Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $24.05M |
| Gross profit | — | — | — | — |
| Net income | $-111.93M | $-154.99M | $-294.23M | $-243.32M |
| Net margin | — | — | — | -1011.7% |
Source: Alumis Inc. SEC filings (10-K).
Alumis Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -1011.7%).
Explore 4 years of Alumis Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALMS in your portfolio →
Alumis Inc. financial history by metric
About Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Alumis Inc. — frequently asked questions
What is Alumis Inc.'s revenue?
Alumis Inc. (ALMS) reported revenue of $24.05M for fiscal year 2025, according to its SEC filings.
Is Alumis Inc. profitable?
No — ALMS reported a net loss of $-243.32M in fiscal 2025.
What is ALMS's P/E ratio?
Alumis Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Alumis Inc. have?
As of fiscal year 2025, ALMS carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Alumis Inc.'s market cap?
Alumis Inc. (ALMS) has a market capitalization of about $2.65B, based on the latest data in our nightly-refreshed cache.
When does Alumis Inc.'s fiscal year end?
ALMS's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Alumis Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.